¢ßÇѺöÅ×Å©³î·ÎÁö
 
 
HOME > NEWS
 
- BSD Medical
- i-CAT
- Ideal Implant
- Mevion
- Sensus HealthCare
- ViewRay
- Viveve
- Xoft
- HanBeam Tech


 
 
ÀÛ¼ºÀÏ : 15-02-06 13:09
iCAD to Showcase its Comprehensive Electronic Brachytherapy Solutions and Services at 56th Annual American Society for Therapeutic Radiology and Oncology (ASTRO) Meeting
 ±Û¾´ÀÌ : ÃÖ°í°ü¸®ÀÚ
Á¶È¸ : 6,432  
   http://www.xoftinc.com/documents/ASTRO2014pressreleasev6091014.pdf [2282]
NASHUA, NH and SAN FRANCISCO (Booth #1938) (September 11, 2014) – iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will debut the Company¡¯s latest technological advances and present updates on clinical data and patient outcomes using the Xoft¢ç Axxent¢ç Electronic Brachytherapy (eBx¢ç) System¢ç in the treatment of cancer during the upcoming American Society for Therapeutic Radiology and Oncology (ASTRO) meeting taking place September 14-17, 2014 at the Moscone Center in San Francisco. Throughout the meeting, iCAD will also showcase its expanded and comprehensive software and service offerings following the recent acquisitions of DermEbx and Radion, and will highlight innovations in technology with live product demonstrations of its Xoft System at Booth #1938.
¡°This is a very exciting year for iCAD as we have significantly expanded our position as the industry¡¯s leading comprehensive solution provider in eBx. We look forward to outlining the elements of our new solutions and services and to giving customers a hands-on experience with our recent advances to the technology platforms including the debut of our Axxent SPX Controller, the latest extension of the Xoft System product line,¡± said Ken Ferry, President and CEO of iCAD. ¡°With our progress this year, iCAD is uniquely positioned to provide significant technology and service advantages to our valued customers and their patients.¡±
¡°We continue to be encouraged by the positive data presented on the Xoft System for the treatment of non-melanoma skin cancer, as it further demonstrates the System¡¯s distinct clinical and cosmetic advantages,¡± added Mr. Ferry.
iCAD Technology Updates and Demonstrations
During ASTRO, iCAD will debut the new Axxent SPX Controller, the latest extension of the Axxent product line. The Axxent SPX Controller features a streamlined design to support enhanced mobility and flexibility for delivery of electronic brachytherapy treatment in a wider range of healthcare settings including smaller treatment rooms. The Axxent SPX Controller also features new software and an enhanced bar code scanning function that offers significant workflow benefits and improved technology support for HIPAA compliance. These features are also now available on the multi-platform Axxent MPX Controller, which remains commercially available as the company¡¯s platform product approved for use in all indications including breast IORT, breast APBI, skin, endometrial and cervical cancer treatments.
¡°Electronic brachytherapy allows radiation oncologists to expand the reach of HDR brachytherapy beyond conventional shielded vaults. It inherently offers safety for patients and personnel, target flexibility for challenging anatomic areas and fine radiation dose control. The new streamlined design may be easier to integrate into smaller spaces in many clinical facilities,¡± said Rakesh Patel, M.D., Medical Director at The Targeted Radiation Institutes in the East and South Bay Areas, CA.
Xoft Systems with the Axxent MPX Controller and the Axxent SPX Controller will both be showcased in the Xoft booth (#1938) at the ASTRO meeting. ASTRO attendees are invited to stop by the booth at any time for a personal demonstration of these technologies or for any additional information. Members of iCAD/Xoft management and clinical experts in eBx will also be available at the Xoft booth for briefings or interviews.
For additional information regarding iCAD and the technologies on display at ASTRO 2014, please visit http://www.xoftinc.com/ASTRO.htm or schedule a live demonstration at http://www.xoftinc.com/contact.html.
iCAD Breakfast Symposium
On Tuesday, September 16, 2014, iCAD will host a Breakfast Symposium entitled: ¡°Clinical Advances in Electronic Brachytherapy for Breast, Skin and Gynecological Cancers.¡± This meeting is open to all ASTRO attendees and will be held from 6:45 am to 7:45 am (PT) at the Industry Expert Theater, ASTRO Exhibit Hall, Room 100.
Presenters at the iCAD breakfast meeting include:
 Ajay Bhatnagar, M.D., MBA (Medical Director, 21st Century Oncology of Arizona, Adjunct Assistant Professor of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA)
 Parag Sanghvi, M.D. (Assistant Professor, Radiation Oncology, University of California San Diego, San Diego, CA)
 Susan Boylan, M.D. (Medical Director, Potomac Radiation Oncology Center, a joint affiliation of Sentara Healthcare and the Inova Health System, Woodbridge, VA)
iCAD Clinical Data Presentation
On Monday, September 15, 2014, Dr. Bhatnagar will present a poster presentation entitled, ¡°Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results up to 4 Years.¡± The poster (#3386) will be presented from 5:30 pm to 6:30 pm (PT) and will be available for viewing beginning at 10:00 am (PT) on Sunday, September 14, 2014.
iCAD Investor Luncheon
In conjunction with the ASTRO meeting, iCAD is hosting an Investor Luncheon on Monday, September 15, 2014 from noon to 2:00 pm (PT) at the San Francisco Marriott Marquis. The meeting will feature a clinical discussion with Dr. Rakesh Patel. For investors interested in attending, please contact Anne Marie Fields, Senior Vice President at LHA, by telephone at (212) 838-377 or by email at afields@lhai.com.
About Xoft Axxent Electronic Brachytherapy System
The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy
tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com